RAPA-201
- Generic Name
- RAPA-201
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
RAPA-201 is an autologous rapamycin-resistant T-cell therapy.
- Associated Conditions
- -
- Associated Therapies
- -
RAPA-201 Therapy of Solid Tumors
Phase 1
Recruiting
- Conditions
- Esophageal AdenocarcinomaGastric Junction AdenocarcinomaSquamous Cell Carcinoma of Oral CavitySmall Cell and Non-small Cell Lung CancerHead and Neck CancerSquamous Cell Carcinoma of Other Specified Sites of SkinSolid TumorTriple Negative Breast CancerGastric CancerSquamous Cell Carcinoma of Larynx
- Interventions
- Biological: RAPA-201 Rapamycin Resistant T CellsDrug: Chemotherapy Prior to RAPA-201 Therapy
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 22
- Registration Number
- NCT05144698
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath